The Institute for Clinical and Economic Review (ICER) has delivered a strong clinical and economic endorsement of today’s leading obesity drugs, while simultaneously warning that U.S. payers are unprepared for the scale of demand these therapies are likely to generate.
In a final evidence report released Tuesday, ICER concluded that Novo Nordisk’s semaglutide (Wegovy, injectable and oral) and Eli Lilly’s tirzepatide (Zepbound) all demonstrate a positive net health benefit when added to lifestyle modification, with an independent appraisal committee voting 14–0 in favor of each therapy.
Committee members agreed the drugs have fundamentally reshaped obesity care, citing not only substantial weight loss but also reductions in cardiovascular risk and improvements across metabolic comorbidities. However, ICER found no clear evidence to distinguish the net health benefit between tirzepatide and injectable semaglutide, nor between oral and injectable semaglutide, underscoring the growing challenge payers face in choosing between clinically similar, high-cost agents.
From a pricing standpoint, ICER determined that all three therapies represent “high” long-term value for money at current net prices, with injectable semaglutide estimated at $6,829 and tirzepatide at $7,973 per year. Oral semaglutide has not yet been approved for obesity, at the same time, ICER assumed price parity with injectable Wegovy for modeling purposes.
ICER’s health benefit price benchmarks (HBPBs) suggest that current pricing remains within value-based ranges: $9,100–$12,500 for injectable semaglutide, $8,300–$11,400 for oral semaglutide, and $11,700–$16,100 for tirzepatide. Even so, ICER leadership emphasized that affordability, not value, will be the binding constraint.
“The population in need is so great that even at cost-effective prices, the U.S. healthcare system will be strained,” ICER Chief Medical Officer David Rind said, pointing to obesity’s prevalence and the likelihood of long-term or lifelong treatment.
Beyond direct clinical outcomes, the committee highlighted broader societal benefits, including improved caregiver productivity and quality of life. ICER also flagged oral semaglutide as a potential access lever, noting that non-injectable delivery could reduce barriers for patients unwilling or unable to use injectables.
Related news
ICER Advances Two High-Stakes Assessments: Cytisinicline Cleared, IgAN Therapies Under Review
The report’s policy recommendations place pressure squarely on payers and manufacturers. ICER urged insurers to avoid restrictive coverage criteria and excessive cost-sharing that could exacerbate disparities, while encouraging drugmakers to consider steep price discounts in exchange for higher volume access. Policymakers and clinical societies were also called on to better equip primary care physicians to manage obesity as a chronic disease.
Taken together, the report delivers a clear message: GLP-1 and GLP-1/GIP drugs have cleared the value bar, but without pricing concessions, coverage reform, and system-level coordination, their real-world impact will fall short of their clinical promise.
For media inquiries or to share perspectives on access and evidence policy, email editor@synopulse.com.
